drugset
drugset / Trial / NCT01843998

Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

NCT01843998 ↗

Phase 2 Withdrawn Stefan Schieke MD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether sirolimus reduces the symptoms of cutaneous T-cell lymphoma (CTCL) and whether it causes any side effects.

Timeline

Start
2014-02
Primary completion
2015-05
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.1 % Topical

Indications

primary cutaneous T-cell lymphoma